Choosing the duration of dual antiplatelet therapy (v1.0 alpha)
For patients at high risk of bleeding treated with complex percutaneous coronary intervention following acute coronary syndrome
About this decision support tool
Authors
Julien Quang Le Van, B.Pharm., M.Sc., BCCP1,2
Marie France Gauthier, Pharm.D., ACPR, BCCP1
Léa Turgeon-Mallette, Pharm D., M.Sc.1
Marie Lordkipanidzé, B.Pharm., Ph.D.1,2
Susan Chen, Pharm.D. M.Sc1
Adèle Goulet, Pharm.D., M.Sc1
Éloi Ravet-Claret, Pharm.D., M.Sc1
Dan Tcaciuc, Pharm.D., M.Sc1
Giulia Matz, Pharm.D.3
Albert Sader, Pharm.D.3
Mohamed Ilyes Tir, Pharm.D.3
Samuel Turcotte, Pharm.D.3
Ricky Turgeon, BPSc(Pharm), ACPR, Pharm.D.4
1Montreal Heart Institute, Quebec, Canada
2Faculty of Pharmacy, University of Montreal, Quebec, Canada
3Master in Advanced Pharmacotherapy candidate, Faculty of Pharmacy, University of Montreal, Quebec, Canada
4Faculty of Pharmaceutical Sciences, University of British Columbia, British Columbia, Canada
Editors
Patients Included
Conflicts of interest declaration
No conflict of interest to declare.
Version: 1.0
© , 2026 all rights reserved - Conflict of Interests - Credits - References